Use of Cooled Radiofrequency for the Treatment of Hip Pain Associated With OA of the Hip Compared to Intra-articular Steroid Injections

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03647332

Enrollment

Registered

2018-08-27

Start date

2017-07-05

Completion date

2019-12-31

Last updated

2018-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteo Arthritis of Hip

Brief summary

This will be a single-center, prospective, single-blinded randomized clinical trial to investigate the effectiveness of using cooled RFA for the treatment of OA hip pain and function in subjects treated with cooled RFA compared with standard of care intra-articular steroid injections

Interventions

PROCEDURECooled RFA treatment

cooled radiofrequency ablation

DRUGSteroid Drug

steroid injection

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Subjects presenting with radiographic evidence of hip OA and demonstrating hip pain for at least 30 days will be targeted. Radiographic evidence of hip OA is defined as Kellegran-Lawrence grade 2-4 * Not an operative candidate as per RI joint replacement surgeon OR * Subjects who do not desire joint replacement surgery after consultation with RI joint replacement surgeon * Male or non-pregnant female older than 18 years of age * willing and able to sign the IRB-approved informed consent document.

Exclusion criteria

* Any steroid injection in hip within 90 days * Local infection at injection site or active systemic infection * Anticoagulation status with inability to discontinue medication for appropriate duration for nerve blocks and RFA given proximity to major artery. (No anticoagulation contraindications for joint injection) * AICD with inability to utilize magnet for RFA per treating cardiologist * Body habitus does not allow for placement of longest needles and electrodes (approximately 15cm) to successfully administer treatment * Allergy or severe renal impairment precluding iodionated contrast or magnavist injection despite standard premedication protocol

Design outcomes

Primary

Measure	Time frame	Description
Pain	24 weeks following treatment	Visual Analog Scale

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026